Cantor Fitzgerald’s MacroGenics MGNX Stock Holding History

Cantor Fitzgerald’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-160,000	Closed	-$269K	–	307
2025 Q3	$269K	Buy	+160,000	New	+$259K	﹤0.01%	342

Other funds holding MGNX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cantor Fitzgerald's MGNX Position: Q4 2025 in Review

Cantor Fitzgerald sold out of MacroGenics (MGNX) in Q4 2025, closing a stake of 160,000 shares — an estimated $269K sold.

Cantor Fitzgerald first reported a position in MGNX in Q3 2025 and held it in 1 quarter. The position peaked at $269K in Q3 2025. 88 funds tracked by Wall St. Rank hold MGNX as of Q4 2025.

Cantor Fitzgerald reported no remaining MacroGenics position as of Q4 2025 after selling out during the quarter.
Cantor Fitzgerald sold 160,000 MacroGenics shares in Q4 2025, an estimated $269K.
Cantor Fitzgerald first reported a position in MacroGenics in Q3 2025 and held it in 1 quarter.
Cantor Fitzgerald's MacroGenics position peaked at $269K in Q3 2025.
88 funds tracked by Wall St. Rank held MacroGenics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.